NCT02008279View on ClinicalTrials.gov

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
BIOLOGICAL

100 mg CNTO 3157

A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157

BIOLOGICAL

300 mg CNTO 3157

2 SC injections of CNTO 3157 providing a total dose of 300 mg

BIOLOGICAL

600 mg CNTO 3157

4 SC injections of CNTO 3157 providing a total dose of 600 mg

BIOLOGICAL

300 mg CNTO 3157

300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes

DRUG

Placebo

SC injections of placebo (number of injections to equal number of injections of CNTO 3157)

Trial Locations (1)

Unknown

Cypress

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02008279 - A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants | Biotech Hunter | Biotech Hunter